Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial

Thomas, 2010, Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia, J Clin Oncol, 28, 3880, 10.1200/JCO.2009.26.9456 Maury, 2016, Rituximab in B-lineage adult acute lymphoblastic leukemia, N Engl J Med, 375, 1044, 10.1056/NEJMoa1605085 Dworzak, 2008, CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy, Blood, 112, 3982, 10.1182/blood-2008-06-164129 Maury, 2010, Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia, Haematologica, 95, 324, 10.3324/haematol.2009.010306 Thomas, 2009, Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia, Blood, 113, 6330, 10.1182/blood-2008-04-151860 Yang, 2017, CD20 expression sub-stratifies standard-risk patients with B cell precursor acute lymphoblastic leukemia, Oncotarget, 8, 105397, 10.18632/oncotarget.22207 Isshiki, 2017, CD20 positivity and white blood cell count predict treatment outcomes in Philadelphia chromosome-negative acute lymphoblastic leukemia patients ineligible for pediatric-inspired chemotherapy, Jpn J Clin Oncol, 47, 1047, 10.1093/jjco/hyx126 Esteban, 2018, Prognostic effect of CD20 expression in adult B-cell acute lymphoblastic leukemia, Clin Lymphoma Myeloma Leuk, 18, 361, 10.1016/j.clml.2018.02.013 Solano-Genesta, 2012, CD20 expression in B-cell precursor acute lymphoblastic leukemia is common in Mexican patients and lacks a prognostic value, Hematology, 17, 66, 10.1179/102453312X13221316477741 Bachanova, 2011, Allogeneic hematopoietic stem cell transplantation overcomes the adverse prognostic impact of CD20 expression in acute lymphoblastic leukemia, Blood, 117, 5261, 10.1182/blood-2011-01-329573 Mannelli, 2012, CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from the molecular study of minimal residual disease, Haematologica, 97, 568, 10.3324/haematol.2011.054064 Marks, 2022, In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial, Lancet Haematol, 9, e276, 10.1016/S2352-3026(22)00036-9 Patel, 2017, Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial, Leukemia, 31, 58, 10.1038/leu.2016.219 Pfeifer, 2019, Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1, Leukemia, 33, 1910, 10.1038/s41375-019-0413-0 Brüggemann, 2010, Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008, Leukemia, 24, 521, 10.1038/leu.2009.268 Weiner, 2010, Rituximab: mechanism of action, Semin Hematol, 47, 115, 10.1053/j.seminhematol.2010.01.011